Ikarian Capital, LLC Fate Therapeutics Inc Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$17.78 - $42.39 $171,399 - $408,639	-9,640 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $17,861 - $36,288	602 Added 6.66%	9,640 $374,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $260,153 - $349,880	5,438 Added 151.06%	9,038 $528,000
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $259,776 - $422,640	3,600 New	3,600 $297,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $196M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.